Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Isabell, Speit"'
Autor:
Karen Kelly, Marcis Bajars, Andrea B Apolo, Juliane Manitz, Sandra P D’Angelo, Isabell Speit, John Warth
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background Adverse events (AEs) of special interest that arise during treatment with immune checkpoint inhibitors, including immune-related AEs (irAEs), have been reported to be associated with improved clinical outcomes. We analyzed patients treated
Externí odkaz:
https://doaj.org/article/ea7fd51fe0894396926faa4a394055c4
Autor:
Isabell Speit, Sandra P. D'Angelo, Karen Kelly, Marcis Bajars, Vijay Kasturi, Arun Rajan, Juliane Manitz, Manish R. Patel, James L. Gulley, Andrea B. Apolo, John Warth
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundAdverse events (AEs) of special interest that arise during treatment with immune checkpoint inhibitors, including immune-related AEs (irAEs), have been reported to be associated with improved clinical outcomes. We analyzed patients treated
Autor:
Karen Kelly, Isabell Speit, Janice M. Mehnert, Anja H. Loos, Nicholas Iannotti, Helga Koch, Manish R. Patel, Deborah J. Wong, James L. Gulley, Matthew H. Taylor, Jeffrey R. Infante
Publikováno v:
Cancer. 124:2010-2017
Author(s): Kelly, Karen; Infante, Jeffrey R; Taylor, Matthew H; Patel, Manish R; Wong, Deborah J; Iannotti, Nicholas; Mehnert, Janice M; Loos, Anja H; Koch, Helga; Speit, Isabell; Gulley, James L | Abstract: BackgroundAntibodies targeting the program
Autor:
Karen, Kelly, Jeffrey R, Infante, Matthew H, Taylor, Manish R, Patel, Deborah J, Wong, Nicholas, Iannotti, Janice M, Mehnert, Anja H, Loos, Helga, Koch, Isabell, Speit, James L, Gulley
Publikováno v:
Cancer
BACKGROUND Antibodies targeting the programmed death‐ligand 1 (PD‐L1)/programmed cell death protein 1 (PD‐1) checkpoint may cause adverse events (AEs) that are linked to the mechanism of action of this therapeutic class and unique from those ob
Autor:
Helga Koch, Deborah Jean Lee Wong, Janice M. Mehnert, Karen Kelly, Isabell Speit, Matthew H. Taylor, Manish R. Patel, Jeffrey R. Infante, Michael S. Gordon, Anja H. Loos, James L. Gulley, Nicholas Iannotti
Publikováno v:
Journal of Clinical Oncology. 35:3059-3059
3059 Background: Avelumab is a fully human IgG1 anti–PD-L1 antibody with clinical activity in several tumor types. Pooled safety data from a large phase 1 trial in various tumors and a phase 2 trial in Merkel cell carcinoma (NCT01772004, NCT0215564
Autor:
Nicholas Iannotti, Karen Kelly, Christopher R. Heery, Marcis Bajars, James L. Gulley, Anja von Heydebreck, Jason C. Chandler, Joseph Leach, Isabell Speit, Manish Patel, Jayne S. Gurtler, Jeffrey R. Infante, Ding Wang, Henrik-Tobias Arkenau, Guy Jerusalem, Petros Nikolinakos
Publikováno v:
Cancer Research. 76:CT132-CT132
Background: The programmed death-1 receptor (PD-1) and its ligand (PD-L1) are key therapeutic targets in the reactivation of the immune response against multiple cancers. Avelumab* (MSB0010718C) is a fully human anti-PD-L1 IgG1 antibody currently bei
Autor:
Howard Safran, Michael S. Gordon, Hendrik-Tobias Arkenau, Karen Kelly, Manish R. Patel, Jean-Marie Cuillerot, Christopher R. Heery, Matthew H. Taylor, Howard L. Kaufman, Jason C. Chandler, Ding Wang, Nicholas Iannotti, Isabell Speit, Joseph W. Leach, James L. Gulley, Deborah Jean Lee Wong, Marcis Bajars, Jeffrey R. Infante, Ulrich Keilholz, Anja von Heydebreck
Publikováno v:
Journal of Clinical Oncology. 34:3055-3055
3055Background: Avelumab* is a fully human anti-PD-L1 IgG1 antibody showing preliminary efficacy in multiple tumor types. We report updated safety data of single-agent avelumab in patients (pts) wi...
Autor:
Manish R. Patel, H-T. Arkenau, James L. Gulley, Berend Neuteboom, Christopher R. Heery, Isabell Speit, Kevin M. Chin, Karen Kelly
Publikováno v:
Annals of Oncology. 26:viii1
Autor:
Kevin M. Chin, Anja von Heydebreck, Ding Wang, Joseph Leach, Isabell Speit, Jayne S. Gurtler, Guy Jerusalem, Hendrik-Tobias Arkenau, Jeffrey R. Infante, Petros Nikolinakos, Jason C. Chandler, James L. Gulley, Manish R. Patel, Karen Kelly, Nicholas Iannotti, Christopher R. Heery
Publikováno v:
Journal of Clinical Oncology. 33:3044-3044
3044 Background: The programmed death-1 receptor (PD-1) and its ligand (PD-L1) are key therapeutic targets in the reactivation of the immune response against multiple cancers. Avelumab* (MSB0010718...
Autor:
Isabell Speit, Harpreet Singh, Geraldine O'Sullivan Coyne, Kevin M. Chin, Lauren M. Lepone, Berend Neuteboom, Jeffrey Schlom, Ravi A. Madan, Jennifer L. Marte, Lisa M. Cordes, Renee N. Donahue, Italia Grenga, Christopher R. Heery, James L. Gulley
Publikováno v:
Journal of Clinical Oncology. 33:3055-3055
3055 Background: The programmed death-1 receptor (PD-1) and its ligand (PD-L1) are key therapeutic targets in the reactivation of the immune response against multiple cancers. Avelumab* (MSB0010718...